< Update


PathoFinder launches second CE-IVD kit for COVID-19 detection

In addition to the RealAccurate® Quadruplex Corona-plus PCR Kit, PathoFinder launches the RealAccurate® Quadruplex  SARS-CoV-2 PCR Kit (CE-IVD), which detects viral RNA from nasopharyngeal swabs and  simultaneously targets the N gene and RdRp gene of the virus, allowing  sensitive detection and confirmation of positive results at once.

The kit is validated on the five most prevalent  real-time instruments, including LightCycler480 II (Roche), Rotor-Gene Q  (Qiagen), MIC qPCR Cycler (BMS), CFX96 (Biorad) and Quantstudio 5 (Thermo  Fisher Scientific).

PathoFinder  has developed in combination with the RealAccuarate® Quadruplex SARS-CoV-2  PCR Kit, an unique extraction-free protocol. The robust composition of the RAQ SARS-CoV-2 PCR Kit  allows replacement of a full nucleic acid extraction procedure by a simple  heat-treatment. This decreases sample processing time and saves on nucleic  acid extraction reagents and disposables.

Although, Ct/Cp values obtained with the  heat-treated samples are slightly higher than those obtained with regular  nucleic acid extraction, overall a nearly comparable sensitivity for  SARS-CoV-2 detection is obtained using heat-treatment. 

For more information go to the PathoFinder website.


Maastricht, June 2020